Safety and Efficacy Study of EndoBarrier in Subjects With Type II Diabetes and Obesity

Type II Diabetes Clinical Trial

Official title:

An Open Label, Randomized, Controlled Study of a Second Generation EndoBarrier™ Liner vs. Diet Control for the Treatment of Type 2 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00985114
• Other study ID #: 07-1
• Status: Completed
• Phase: N/A
• First received: September 25, 2009
• Last updated: March 9, 2015
• Start date: October 2009
• Est. completion date: January 2013

Study information

• Verified date: August 2010
• Source: GI Dynamics
• Contact: n/a
• Is FDA regulated: No
• Health authority: Netherlands: Medical Ethics Review Committee (METC)
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of a second generation EndoBarrier Liner compared to a study diet to treat Subjects with Type 2 Diabetes.

This is a randomized, controlled study which will enroll approximately 70 Subjects with Type 2 Diabetes. Randomization will be one to one with approximately 35 EndoBarrier device Subjects and approximately 35 study diet Subjects. Subjects randomized as diet Subjects will be offered the EndoBarrier device after 12 months on study at the investigator's discretion if treatment of the device subjects indicates adequate efficacy. This study will be conducted at three (3) investigational sites.

The primary efficacy endpoint is:

• Assessment of the percent (%) of Subjects who achieve a ≥ 0.5% reduction in HbA1C at 24 weeks or last visit from baseline between the two groups.

Secondary endpoints are:

• Percent (%) of Subjects who achieve a HbA1C of 7.0% or lower at week 24 or last visit from baseline.

• Percent (%) of Subjects who have their diabetic medication(s) dosage decreased or discontinued at week 24 or last visit from baseline.

• Percent (%) of Subjects who achieve a decrease in post-prandial excursions as evidenced by challenge to a standardized meal tolerance test (MTT) at week 24 or last visit from baseline.

• Assessment of absolute weight loss (Kg) at week 24 or last visit from baseline.

• Percent (%) of Subjects who maintain a HbA1c lower than their baseline assessment at 12 months.

• Compare physical component summary (PCS), mental component summary (MCS) and quality adjusted life years (QALYs)via analysis of the SF-36v2 QOL.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Age > 18 years and < 65 years

• Male or Female

• Subjects with Type 2 Diabetes who have been treated for =10 years

• BMI> 30 - < 50

• Subjects with an HbA1c level > 7.5 and = 10.0%

• Subjects taking a combination of metformin and sulfonylureas and/or insulin (other than pre-mixed long and short acting insulins, ie. NovoMix 30)

• Patients willing to comply with study requirements

• Patients who have signed an informed consent form

Exclusion Criteria:

• Subjects taking oral medications to control their diabetes other than sulfonylureas and metformin

• Subjects diagnosed with Type 1 Diabetes Mellitus or having a history of ketoacidosis

• Subjects on insulin > 10 years

• Subjects requiring insulin > 70 units per day

• Subjects on pre-mixed insulin (ie. NovoMix 30)

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 2
• Type II Diabetes

Intervention

Device:
• EndoBarrier
EndoBarrier implant

Behavioral:
• Diet + Lifestyle Counseling
Multidisciplinary lifestyle and nutritional counseling

Locations

Country	Name	City	State
Netherlands	Ziekenhuis Rijnstate Arnhem	Arnhem
Netherlands	Medisch Centrum Parkstad	Heerlen
Netherlands	University Hospital Maastricht	Maastricht

Sponsors (1)

Lead Sponsor	Collaborator
GI Dynamics

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent (%) of Subjects who achieve a = 0.5% reduction in HbA1C at 24 weeks or last visit from baseline.		6 months	No